Natera Inc (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 2,859 Shares

Natera Inc (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 2,859 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $37.50, for a total value of $107,212.50. Following the completion of the sale, the chief financial officer now directly owns 16,630 shares in the company, valued at $623,625. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Michael Burkes Brophy also recently made the following trade(s):

  • On Wednesday, October 30th, Michael Burkes Brophy sold 2,859 shares of Natera stock. The stock was sold at an average price of $38.25, for a total value of $109,356.75.
  • On Monday, October 21st, Michael Burkes Brophy sold 15,701 shares of Natera stock. The shares were sold at an average price of $40.00, for a total value of $628,040.00.
  • On Monday, September 30th, Michael Burkes Brophy sold 4,032 shares of Natera stock. The shares were sold at an average price of $32.01, for a total value of $129,064.32.
  • On Monday, September 23rd, Michael Burkes Brophy sold 444 shares of Natera stock. The stock was sold at an average price of $33.53, for a total value of $14,887.32.
  • On Friday, September 20th, Michael Burkes Brophy sold 9,972 shares of Natera stock. The stock was sold at an average price of $33.19, for a total transaction of $330,970.68.
  • On Tuesday, September 10th, Michael Burkes Brophy sold 1,206 shares of Natera stock. The shares were sold at an average price of $29.50, for a total transaction of $35,577.00.
  • On Wednesday, September 4th, Michael Burkes Brophy sold 78 shares of Natera stock. The shares were sold at an average price of $32.49, for a total transaction of $2,534.22.

Shares of NASDAQ:NTRA opened at $34.12 on Wednesday. The company has a market cap of $2.83 billion, a P/E ratio of -15.87 and a beta of 1.40. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.35 and a quick ratio of 2.26. Natera Inc has a 1 year low of $11.08 and a 1 year high of $40.92. The stock’s fifty day moving average price is $38.20 and its 200-day moving average price is $30.87.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Wednesday, November 6th. The medical research company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.20. Natera had a negative return on equity of 252.79% and a negative net margin of 42.45%. The company had revenue of $77.90 million for the quarter, compared to analysts’ expectations of $73.97 million. During the same period last year, the firm posted ($0.49) earnings per share. Natera’s revenue was up 19.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Natera Inc will post -2.15 earnings per share for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of NTRA. Lagoda Investment Management L.P. purchased a new stake in shares of Natera during the 3rd quarter valued at about $669,000. Metropolitan Life Insurance Co NY lifted its position in Natera by 55.8% during the third quarter. Metropolitan Life Insurance Co NY now owns 18,488 shares of the medical research company’s stock valued at $606,000 after purchasing an additional 6,621 shares during the period. Millennium Management LLC lifted its position in Natera by 1,562.8% during the third quarter. Millennium Management LLC now owns 2,191,733 shares of the medical research company’s stock valued at $71,888,000 after purchasing an additional 2,059,920 shares during the period. Man Group plc purchased a new stake in Natera in the third quarter worth approximately $2,791,000. Finally, California State Teachers Retirement System boosted its holdings in Natera by 1.1% in the third quarter. California State Teachers Retirement System now owns 87,100 shares of the medical research company’s stock worth $2,857,000 after purchasing an additional 950 shares during the last quarter. Institutional investors and hedge funds own 84.90% of the company’s stock.

NTRA has been the subject of several recent analyst reports. Craig Hallum lifted their target price on shares of Natera from $37.00 to $49.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. increased their price target on shares of Natera from $27.00 to $32.00 and gave the company a “neutral” rating in a report on Monday, November 4th. BidaskClub cut shares of Natera from a “strong-buy” rating to a “buy” rating in a report on Saturday. ValuEngine downgraded shares of Natera from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Canaccord Genuity restated a “buy” rating and issued a $44.00 price objective on shares of Natera in a report on Wednesday, October 16th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Natera has an average rating of “Buy” and an average target price of $42.50.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

See Also: Initial Coin Offering (ICO)

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit